×
ADVERTISEMENT

HER2-low

Patients With HER2-Low Early Breast Cancer Respond to Trastuzumab Deruxtecan

Neoadjuvant trastuzumab deruxtecan (T-DXd) (Enhertu, Daiichi Sankyo) produced responses and decreased HER2 ...

DECEMBER 28, 2022

Load more